Fentanyl is a potent, synthetic opioid analgesic with a rapid onset and short duration of action. Recently, there have been many case reports that overuse or misuse of fentanyl patch resulted in fatal intoxication. Delayed hypoxic leukoencephalopathy typically manifests 2 to 40 days after apparent recovery from hypoxic event, and patients suffer from cognitive impairment, upper motor neuron signs, gait disturbance, or psychosis. We report first case of delayed encephalopathy with psychotic symptoms after overuse of fentanyl patch. Patient was found to have respiratory failure and mental change due to transdermal fentanyl overdose. She made a complete recovery in 2 weeks. After 4 weeks of the event, she readmitted with declining mental status. At 30 weeks after overdose, she complained of auditory and visual hallucination and showed paranoid delusion and odd behavior. Since admission into psychiatric unit, her psychotic symptoms have improved with antipsychotics. In conclusion, fentanyl patch should be used in order to prevent psychotic symptoms as well as medical complications.
Antipsychotic Agents ; Delusions ; Fentanyl* ; Gait ; Hallucinations ; Humans ; Leukoencephalopathies ; Motor Neurons ; Psychotic Disorders* ; Respiratory Insufficiency

OBJECTIVE: In Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), a new specifier of major depressive disorder (MDD) "with anxious distress" allows characterization of additional symptoms. The aim of this study was to investigate difference in treatment outcome of MDD with versus without anxious distress specifier in DSM-5. METHODS: Retrospective chart review of patients admitted to a university hospital with a primary diagnosis of MDD in a period from March 2013 to September 2014 was conducted. We reviewed anxious distress symptoms, medications and detailed clinical information at index episode. We compared treatment outcomes of anxious distress group with those of non anxious distress group. RESULTS: There were differences in remission rate after 4 weeks later (18.5% vs. 44.4%, p=0.040) and at discharge (33.3% vs. 66.7%, p=0.014) between anxious distress and non anxious distress. However, no significant differences were observed in the sociodemographic characteristics, treatment regimens, and response rate. CONCLUSION: Anxious distress specifier might be worthwhile to be further evaluated as a diagnostic entity of its own requiring specific diagnosis and therapeutic attention.
Depression* ; Depressive Disorder, Major ; Diagnosis ; Diagnostic and Statistical Manual of Mental Disorders ; Humans ; Retrospective Studies ; Treatment Outcome*

OBJECTIVE: The aim of this study was to investigate the relationship between subjective anxiety symptoms and cognitive function in patients with mild traumatic brain injury. METHODS: A total 48 patients were recruited in this study. All participants were divided into two groups by anxiety symptoms in Hospital Depression and Anxiety Scale. Intelligence Scale and memory test were analyzed. RESULTS: A high risk group showed lower scores in all of verbal intelligence quotient (IQ) and total IQ in Intelligence Scale and memory quotient in memory test. CONCLUSION: This study suggests that anxiety symptoms make worse in cognitive function in patients with mild traumatic brain injury.
Anxiety* ; Brain Injuries* ; Depression ; Humans ; Intelligence ; Memory

OBJECTIVE: Korea Institute of Drug Safety and Risk Management works for signal detection and safety information generation by analyzing spontaneous adverse event reports database. As the number of reports and detected signals of aripiprazole by each data mining indices were more than other drugs, aripiprazole was selected as a subject of study. METHODS: 1989-2012 spontaneous reporting database was analyzed and the model drug ingredient was aripiprazole. We estimated proportional reporting ratio, reporting odds ratio, and information component for data mining. Then we assessed the causality through review of local and foreign drug labels and literatures. RESULTS: In reconstructed 1989-2012 spontaneous reporting database, there were 2,062 reports on aripiprazole and 2,565 aripiprazole-adverse events pairs. As a result of data mining analysis and signal prioritization, 78 adverse events were detected, 20 adverse events of them were not included in drug label. After literature review, back pain, epistaxis, xerophthalmia and ejaculation disorder were generated as novel safety information on aripiprazole. CONCLUSION: Those 4 novel safety informations of Aripiprazole, back pain, epistaxis, xerophthalmia and ejaculation disorder had become listed on the local label in April 2013.
Back Pain ; Data Mining ; Ejaculation ; Epistaxis ; Korea ; Male ; Odds Ratio ; Risk Management ; Xerophthalmia ; Aripiprazole

Stress and trauma research has traditionally focused on negative sequelae of adversity. Recently, research has begun to focus on positive outcomes, specifically post-traumatic growth (PTG) - "positive change experienced as a result of the struggle with trauma" - which emphasizes the transformative potential of one's experiences with highly stressful events and circumstances. This article describes the concept of PTG at three different perspectives. In addition we reviewed the neurobiological factors and mechanism of PTG. It has shown that PTG is mediated by adaptive changes in several neural circuits involving numerous neurotransmitter and molecular pathways. Much more study is required to achieve a deeper understanding the biological and psychological underpinnings of PTG, as well as the interactions between these factors. After all, the clinical phenomenology of PTG is very important for mental growth after trauma. The findings of this article provide further directions for research and clinical implication of PTG.
Fertilization* ; Life Change Events ; Neurobiology* ; Neurotransmitter Agents

We report a case of a 34-year-old woman who was in temporary delirium and hyperammonemia during treatment of bipolar affective disorder with valproate. Patient showed delirium after 20 days of treatment, while the serum valproate level was within the therapeutic range without any sign of hepatic insufficiency. However, the patient had increased serum ammonia level (121 microg/mL), and valproate was discontinued due to suspicion of valproate-induced hyperammonemic encephalopathy (VHE). Serum valproate level was normalized with reduced delirium after valproate has been discontinued. Few VHE in psychiatric literature has been documented, because of possible confusion between VHE and preexisting psychiatric symptoms. Clinicians should be cautious about the potential risk for hyperammonemic encephalopathy caused by valproate medication.
Adult ; Ammonia ; Delirium ; Female ; Hepatic Insufficiency ; Humans ; Hyperammonemia ; Mood Disorders ; Valproic Acid

Hyperprolactinemia is a well-known neuroendocrine side effect to antipsychotic agent. Combined treatment of aripiprazole is recognized as an effective solution against hyperprolactinemia caused by antipsychotic agent. We report 2 progressive clinical cases where both are treated with combined use of aripiprazole which has a unique mechanism of action to resolve olanzapine and amisulpride-induced hyperprolactinemia.
Hyperprolactinemia*

OBJECTIVE: Sleep problems are a prominent feature in children with attention-deficit/hyperactivity disorder (ADHD) and about 25-43% of ADHD patients were reported to have sleep problems including higher level of nocturnal activity, longer sleep latency, lower sleep efficiency, more frequent night awakenings and shorter total sleep time. However, the association between sleep and ADHD is poorly understood and their relationships to sleep structure are not consistent across studies. The aims of our study were to ascertain the nocturnal sleep disturbances in patients with ADHD by objective measure, polysomnography. METHODS: The subjects were 20 patients with ADHD and 21 control children (6-12 years). We tested them by polysomnography to get sleep variables and compare sleep disturbances. In addition, we tested ADHD group by neurocognitive function test and assessed the correlation between sleep variables and neurocognitive functions in ADHD group. RESULTS: In sleep variables by polysomnography, the total time in bed (509.73+/-24.56 min vs. 490.51+/-20.71 min, p=0.01), sleep latency (21.30+/-19.33 min vs. 10.72+/-7.26 min, p=0.031) and limb movement arousal (6.56+/-2.19 /hr vs. 5.98+/-1.38 /hr, p=0.043) were significantly increased in patients with ADHD compared with controls. And the slow wave sleep (24.59+/-4.73% vs. 28.45+/-5.63%, p=0.023) were significantly decreased in patients with ADHD compared with controls. There were no significant differences in sleep period time and sleep efficiency test. CONCLUSION: The patients with ADHD had more sleep problems and results of this study suggested that they have significantly increased the total time in bed, sleep latency and Limb movement arousal. And in the patients with ADHD, some sleep variables indicated poor sleep quality. However, further studies should repeatedly suggest consistent results about sleep problems in children with ADHD.
Arousal ; Child* ; Extremities ; Humans ; Polysomnography*

OBJECTIVE: Finding out patient's non-adherence to medication is an important work for treating schizophrenia. The Medication Adherence Rating Scale is a self-report form, which can simply measure medication adherence in psychosis. We evaluated the reliability and validity of the Korean version of Medication Adherence Rating Scale (KMARS). METHODS: Eighty-one individuals with schizophrenia completed the self-administered questionnaires including KMARS, Brief Adherence Rating Scale (BARS), Korean version of Drug Attitude Inventory-10 (KDAI-10) and Korean version of Medication Adherence Questionnaire (KMAQ). Psychometric properties of the KMARS were analyzed. RESULTS: The KMARS has an acceptable internal consistency (alpha=0.71). The KMARS total scores are moderately correlated with BARS (r=0.44, p<0.01), KDAI-10 (r=0.55, p<0.01) and KMAQ (r=0.62, p<0.01). As the result of factor analysis, the structure of the KMARS is different from original scale, but the KMARS can assess not only adherence behavior but also subjective response to medication. Among the questions item 5, "I take my medication only when I am sick", should be used carefully, because it has ambiguous meaning in Korean. CONCLUSION: KMARS is a simple and reliable tool for measuring medication adherence in psychosis.
Medication Adherence* ; Psychometrics ; Psychotic Disorders ; Surveys and Questionnaires ; Reproducibility of Results* ; Schizophrenia

OBJECTIVE: Although clinical guidelines recommend that antidepressant treatment should be continued for at least 4 to 9 months, naturalistic studies show that the average length of treatment is shorter than 6 months and that dropout rates are high. But factors leading patients to discontinuation of therapy are not well understood yet. In this study, we investigated factors associated with adherence to antidepressant in Korean patients with depressive disorder. METHODS: Patients who were diagnosed as depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders-4th edition criteria and took prescribed antidepressants were included in this study. Medical records of 194 patients were reviewed retrospectively. To find adherence to antidepressant treatment, we calculated Medication Possession Ratio at 2 wks, 4 wks, 8 wks, 12 wks, 24 wks after their 1st visit. Patient-related factors, illness-related factors including measurement scales (Beck Depression Inventory, Patient Health Questionnare-15, Global Assessment of Recent Stress Scale scores), and treatment-related factors were compared between adherent group and non-adherent group using chi-square test or student t-test. Multivariate logistic regression was used to predict factors associated with adherence to antidepressant treatment. RESULTS: Analyzing data of 194 patients, 106 patients (54.6%), and 82 patients (42.3%) were adherent group at 12 wks and 24 wks, respectively. In patient-related factors, old age and low education periods were significantly associated with adherent group. In illness-related factors and treatment-related factors, none of the factors showed a significant difference between groups. In multivariate logistic regression, old age was significantly associated with sustained adherence at 12 wks. CONCLUSION: We found some factors associated with adherence to antidepressant treatment. Old age was associated with sustained adherence to antidepressant. To enhance adherence to antidepressant, our findings suggest that outpatient education program is needed. And social policy is also essential to reduce stigma in psychiatric department especially among young patients.
Antidepressive Agents ; Depression ; Depressive Disorder* ; Education ; Humans ; Logistic Models ; Medical Records ; Outpatients* ; Patient Dropouts ; Public Policy ; Retrospective Studies ; Weights and Measures